As promised, AstraZeneca is forging ahead with its cast-off strategy—and this time, it’s rights to an aged beta-blocker that’s are on their way out the door.

A fight has emerged between countries vying for the economic lift and status that come with hosting the EMA.

The FDA has approved an immuno-oncology med as a new treatment for bladder cancer—for the third week in a row. Only this one has positive overall survival data…

Dead set on defending its top drug, Johnson & Johnson is taking South Korea’s Samsung Bioepis to federal court over a biosim launch.

China's FDA proposed several drug policy changes, Indian drugmakers cashed out on generics and BI opened a Shanghai plant.

Rare disease drugmakers get that their typically high prices are under the lens these days—just like everyone else’s. But they don’t all necessarily agree that…

Investors are eager for data that determines how Eli Lilly’s abemaciclib stacks up against Pfizer’s Ibrance in the efficacy department. But analysts say they’…

A new study finds that Merck’s Gardasil may provide additional protection not included in its official FDA label.

Pharma